Literature DB >> 19786601

Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

M Mar Rodríguez1, F Javier Pastor, Enrique Calvo, Valentina Salas, Deanna A Sutton, Josep Guarro.   

Abstract

A broth microdilution method was used to evaluate the in vitro activities of seven antifungal agents against 15 clinical strains of Rhizopus microsporus. Amphotericin B (AMB) and posaconazole (POS) were the most active drugs. In a model of disseminated R. microsporus infection in immunosuppressed mice, we studied the efficacy of POS administered once or twice daily against four of the strains previously tested in vitro and compared it with that of liposomal AMB (LAMB). LAMB was the most effective treatment for the two strains with intermediate susceptibility to POS. For the two POS-susceptible strains, LAMB and POS at 20 mg/kg of body weight twice a day orally showed similar efficacies. The in vivo efficacy of POS administered twice a day orally correlated with the in vitro susceptibility data and the serum drug concentrations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786601      PMCID: PMC2786372          DOI: 10.1128/AAC.01026-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

Authors:  Shawn A Messer; Daniel J Diekema; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

2.  In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Authors:  Nikolaos G Almyroudis; Deanna A Sutton; Annette W Fothergill; Michael G Rinaldi; Shimon Kusne
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

3.  Posaconazole concentrations in the central nervous system.

Authors:  Maria J G T Rüping; Nadine Albermann; Friedrich Ebinger; Irene Burckhardt; Claudia Beisel; Carsten Müller; Jörg J Vehreschild; Matthias Kochanek; Gerd Fätkenheuer; Christopher Bangard; Andrew J Ullmann; Wolfgang Herr; Karin Kolbe; Michael Hallek; Oliver A Cornely
Journal:  J Antimicrob Chemother       Date:  2008-09-28       Impact factor: 5.790

4.  Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

Authors:  Ana Alastruey-Izquierdo; Maria Victoria Castelli; Isabel Cuesta; Araceli Monzon; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

Review 5.  Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.

Authors:  Michele I Morris
Journal:  Am J Health Syst Pharm       Date:  2009-02-01       Impact factor: 2.637

6.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.

Authors:  M Mar Rodríguez; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

8.  Posaconazole as first line treatment for disseminated zygomycosis.

Authors:  Trisha Peel; John Daffy; Karin Thursky; Peter Stanley; Kirsty Buising
Journal:  Mycoses       Date:  2008-04-16       Impact factor: 4.377

9.  Posaconazole mono- or combination therapy for treatment of murine zygomycosis.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Julie A Schwartz; John E Edwards; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2008-10-20       Impact factor: 5.191

10.  Disseminated Rhizopus microsporus infection in a patient on oral corticosteroid treatment: a case report.

Authors:  P de Mol; J F G M Meis
Journal:  Neth J Med       Date:  2009-01       Impact factor: 1.422

View more
  14 in total

1.  Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

Authors:  J J Vehreschild; C Müller; F Farowski; M J G T Vehreschild; O A Cornely; U Fuhr; K-A Kreuzer; M Hallek; V Kohl
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

2.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

3.  Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.

Authors:  A Espinel-Ingroff; A Chakrabarti; A Chowdhary; S Cordoba; E Dannaoui; P Dufresne; A Fothergill; M Ghannoum; G M Gonzalez; J Guarro; S Kidd; C Lass-Flörl; J F Meis; T Pelaez; A M Tortorano; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

4.  Rapidly progressive cutaneous Rhizopus microsporus infection presenting as Fournier's gangrene in a patient with acute myelogenous leukemia.

Authors:  C M Durand; C D Alonso; A P Subhawong; N P Kwiatkowski; M Showel; K C Carroll; K A Marr
Journal:  Transpl Infect Dis       Date:  2011-03-28       Impact factor: 2.228

5.  Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.

Authors:  M Mar Rodríguez; F Javier Pastor; Deanna A Sutton; Enrique Calvo; Annette W Fothergill; Valentina Salas; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

6.  Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.

Authors:  Russell E Lewis; Nathaniel D Albert; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

7.  In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.

Authors:  Valentina Salas; F Javier Pastor; Enrique Calvo; Eduardo Alvarez; Deanna A Sutton; Emilio Mayayo; Anette W Fothergill; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

8.  Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.

Authors:  Laura Friggeri; Tatiana Y Hargrove; Girish Rachakonda; Anna L Blobaum; Paxtyn Fisher; Gabriel Melo de Oliveira; Cristiane França da Silva; Maria de Nazaré C Soeiro; W David Nes; Craig W Lindsley; Fernando Villalta; F Peter Guengerich; Galina I Lepesheva
Journal:  J Med Chem       Date:  2018-11-30       Impact factor: 7.446

9.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

10.  VNI cures acute and chronic experimental Chagas disease.

Authors:  Fernando Villalta; Mark C Dobish; Pius N Nde; Yulia Y Kleshchenko; Tatiana Y Hargrove; Candice A Johnson; Michael R Waterman; Jeffrey N Johnston; Galina I Lepesheva
Journal:  J Infect Dis       Date:  2013-01-31       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.